Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Recommendation of “Buy” from Brokerages

Aquestive Therapeutics, Inc. (NASDAQ:AQST) has received a consensus recommendation of “Buy” from the seven research firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, four have issued a buy rating and two have given a strong buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $8.50.

A number of brokerages have commented on AQST. Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Monday, April 20th. Oppenheimer assumed coverage on shares of Aquestive Therapeutics in a research note on Friday, April 24th. They issued an “outperform” rating and a $8.00 target price for the company. Finally, Wall Street Zen upgraded shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th.

Insider Buying and Selling

In other news, CEO Daniel Barber sold 8,257 shares of Aquestive Therapeutics stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $4.29, for a total value of $35,422.53. Following the completion of the transaction, the chief executive officer owned 660,574 shares in the company, valued at approximately $2,833,862.46. The trade was a 1.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Julie Krop sold 25,000 shares of Aquestive Therapeutics stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $5.02, for a total transaction of $125,500.00. Following the completion of the transaction, the director owned 25,000 shares of the company’s stock, valued at $125,500. This trade represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.81% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. NewEdge Advisors LLC bought a new position in shares of Aquestive Therapeutics in the third quarter valued at approximately $28,000. BNP Paribas Financial Markets raised its position in Aquestive Therapeutics by 78.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock worth $31,000 after purchasing an additional 4,134 shares during the last quarter. Modern Wealth Management LLC bought a new position in Aquestive Therapeutics in the 2nd quarter worth approximately $33,000. Elevation Point Wealth Partners LLC bought a new position in Aquestive Therapeutics in the 1st quarter worth approximately $42,000. Finally, ADAR1 Capital Management LLC raised its position in Aquestive Therapeutics by 103.9% in the 1st quarter. ADAR1 Capital Management LLC now owns 10,000 shares of the company’s stock worth $42,000 after purchasing an additional 264,000 shares during the last quarter. Institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Price Performance

Shares of AQST opened at $4.16 on Wednesday. The stock has a market cap of $521.96 million, a price-to-earnings ratio of -6.82 and a beta of 1.46. Aquestive Therapeutics has a 12 month low of $2.93 and a 12 month high of $7.55. The company has a 50-day moving average price of $4.22 and a two-hundred day moving average price of $4.35.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.07. The business had revenue of $14.45 million for the quarter, compared to the consensus estimate of $10.90 million. Equities research analysts expect that Aquestive Therapeutics will post -0.41 EPS for the current fiscal year.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.